Viatris Inc. (VTRS)

The company now

Viatris reported second-quarter 2026 total revenues of $3.8 billion on 6 August, up 5 percent from a year earlier 1. It posted a U.S. GAAP net loss of $119 million, driven mainly by a non-cash charge of $177.8 million tied to the planned sale of the Tyrvaya product rights 1.

Adjusted earnings per share, a measure that leaves out one-time items, was $0.69, up 11 percent 1. The company raised its 2026 revenue guidance to a range of $14.55 billion to $14.95 billion 1.

The bigger news since is a purchase, as on 8 October Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion 2. Pacira makes Exparel and Zilretta, two non-opioid pain medicines 2.

The tender offer, the step in which Pacira's owners hand their shares over, is set to expire on 16 November 9. The company expects the deal to close by the end of 2026 2.

Third-quarter results are due on 5 November 8. The company expects supply problems at its Nashik plant in India to cut total revenues by $100 million to $150 million in the second half of 2026 1.

As of Nov 3, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.